NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - Feb 14, 2013) - William Dolphin, Ph.D., the CEO of regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), was interviewed by SNNLive last week. Dr. Dolphin provides an update on Avita's flagship product, ReCell® Spray‐On Skin®. Based on Avita's proprietary technology, ReCell is designed to provide a rapid, safe and effective point of care treatment for regrowing skin tissue that has been damaged due to trauma, disease, or senescence.
Watch the video here:
Dr. Dolphin emphasizes that ReCell® addresses a wide range of markets including "acute wounds, burns, chronic wounds, diabetic foot ulcers, venous leg ulcers, plastic reconstructive, acne scarring, and vitiligo." The interview showcases a comprehensive overview of Avita Medical, touching on company history, products overview, current and pending approvals, and market size potential. Dr. Dolphin also discusses Avita's strategy of building the foundation for growth via clinical studies, research and development, and reimbursement.
For more information, please visit Avita's website at http://www.avitamedical.com.
ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.